EGFR antibody (pTyr1173) (Alexa Fluor 647)
-
- Target See all EGFR Antibodies
- EGFR (Epidermal Growth Factor Receptor (EGFR))
-
Binding Specificity
- pTyr1173
-
Reactivity
- Human, Mouse, Rat, Dog
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This EGFR antibody is conjugated to Alexa Fluor 647
-
Application
- Intracellular Staining (ICS)
- Brand
- BD Phosflow™
- Purification
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
- Immunogen
- Phosphorylated Human EGF Receptor Peptide
- Clone
- 9H2
- Isotype
- IgG1 kappa
- Top Product
- Discover our top product EGFR Primary Antibody
-
-
- Sample Volume
- 20 μL
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C
- Storage Comment
- Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The antibody was conjugated to Alexa Fluor® 647 under optimum conditions, and unreacted Alexa Fluor® 647 was removed.
-
-
The ErbB signaling network: receptor heterodimerization in development and cancer." in: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, (2000) (PubMed).
: "
-
The ErbB signaling network: receptor heterodimerization in development and cancer." in: The EMBO journal, Vol. 19, Issue 13, pp. 3159-67, (2000) (PubMed).
-
- Target
- EGFR (Epidermal Growth Factor Receptor (EGFR))
- Alternative Name
- EGF Receptor (EGFR Products)
- Synonyms
- C-erb antibody, CG10079 antibody, D-EGFR antibody, D-Egf antibody, DEGFR antibody, DER antibody, DER flb antibody, DER/EGFR antibody, DER/faint little ball antibody, DER/top antibody, DER/torpedo antibody, DER1 antibody, DEgfr antibody, Degfr antibody, Der antibody, DmHD-33 antibody, Dmel\\CG10079 antibody, EFG-R antibody, EGF-R antibody, EGFR antibody, EGFr antibody, EGfr antibody, EK2-6 antibody, Egf antibody, Egf-r antibody, EgfR antibody, El antibody, Elp antibody, Elp-1 antibody, Elp-B1 antibody, Elp-B1RB1 antibody, HD-33 antibody, TOP antibody, Torpedo/DER antibody, Torpedo/Egfr antibody, c-erbB antibody, d-egf-r antibody, dEGFR antibody, dEGFR1 antibody, dEgfr antibody, der antibody, egfr antibody, flb antibody, l(2)05351 antibody, l(2)09261 antibody, l(2)57DEFa antibody, l(2)57EFa antibody, l(2)57Ea antibody, mor1 antibody, top antibody, top/DER antibody, top/flb antibody, torpedo/Egfr antibody, torpedo/egfr antibody, EGFR12 antibody, EGFR15 antibody, egfr1 antibody, Erbb2 antibody, ERBB antibody, ERBB1 antibody, HER1 antibody, PIG61 antibody, mENA antibody, ErbB-1 antibody, Errp antibody, 9030024J15Rik antibody, AI552599 antibody, Erbb antibody, Errb1 antibody, Wa5 antibody, wa-2 antibody, wa2 antibody, epidermal growth factor receptor antibody, Epidermal growth factor receptor antibody, epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) antibody, EGFR antibody, Egfr antibody, egfra antibody, egfr1 antibody, LOC5564544 antibody
- Background
- Epidermal Growth Factor (EGF) elicits a variety of cellular responses that are initiated by EGF Receptor (EGFR) binding and activation of intrinsic tyrosine kinase activity. EGFR, also known as ErbB1 or HER1, is a member of the ErbB class of receptor protein tyrosine kinases. It has an extracellular ligand-binding domain, a single transmembrane region, and a cytoplasmic region containing a protein tyrosine kinase domain and a c-terminal regulatory domain with many phosphorylation sites. Following ligand binding, EGFR forms homodimers and heterodimers with ErbB2. Specific C-terminal tyrosine residues are then autophosphorylated and, in turn, bind to adaptor proteins, kinases, or protein tyrosine phosphatases. Specifically, phosphorylated tyrosine 1173 (Y1173) interacts with Shc, SHP1, and PLCg, which mediate downstream signaling cascades and negative feedback regulation of EGFR activation. Inappropriate expression or mutations of EGFR and/or deregulation of its signaling pathways are associated with many types of cancer, making EGFR a promising target for cancer therapies. The 9H2 monoclonal antibody recognizes the phosphorylated Y1173 in the regulatory domain of human EGFR.
- Pathways
- NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteins
-